Ultragenyx Pharmaceutical Inc (RARE)
46.00
-0.40
(-0.86%)
USD |
NASDAQ |
Nov 21, 16:00
46.00
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Net Income (Quarterly): -133.52M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -133.52M |
| June 30, 2024 | -131.60M |
| March 31, 2024 | -170.68M |
| December 31, 2023 | -123.19M |
| September 30, 2023 | -159.65M |
| June 30, 2023 | -159.83M |
| March 31, 2023 | -163.97M |
| December 31, 2022 | -151.83M |
| September 30, 2022 | -245.11M |
| June 30, 2022 | -158.16M |
| March 31, 2022 | -152.32M |
| December 31, 2021 | -122.46M |
| September 30, 2021 | -73.00M |
| June 30, 2021 | -122.43M |
| March 31, 2021 | -136.14M |
| December 31, 2020 | -24.01M |
| September 30, 2020 | -68.84M |
| June 30, 2020 | 25.32M |
| March 31, 2020 | -119.02M |
| December 31, 2019 | -93.80M |
| September 30, 2019 | -112.99M |
| June 30, 2019 | -99.17M |
| March 31, 2019 | -96.76M |
| December 31, 2018 | -87.83M |
| Date | Value |
|---|---|
| September 30, 2018 | -87.31M |
| June 30, 2018 | -52.73M |
| March 31, 2018 | 30.25M |
| December 31, 2017 | -81.73M |
| September 30, 2017 | -79.23M |
| June 30, 2017 | -72.89M |
| March 31, 2017 | -68.29M |
| December 31, 2016 | -71.29M |
| September 30, 2016 | -64.91M |
| June 30, 2016 | -56.92M |
| March 31, 2016 | -52.76M |
| December 31, 2015 | -55.22M |
| September 30, 2015 | -39.23M |
| June 30, 2015 | -29.79M |
| March 31, 2015 | -21.38M |
| December 31, 2014 | -16.74M |
| September 30, 2014 | -15.85M |
| June 30, 2014 | -13.58M |
| March 31, 2014 | -13.63M |
| December 31, 2013 | -11.32M |
| September 30, 2013 | -8.428M |
| June 30, 2013 | -8.59M |
| March 31, 2013 | -6.735M |
| December 31, 2012 | -4.93M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-245.11M
Minimum
Sep 2022
25.32M
Maximum
Jun 2020
-124.21M
Average
-132.56M
Median
Net Income (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -111.57M |
| NovaBay Pharmaceuticals Inc | -1.212M |
| Palatin Technologies Inc | -7.824M |
| iBio Inc | -3.989M |
| Theriva Biologics Inc | -7.726M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 139.49M |
| Total Expenses (Quarterly) | 271.48M |
| EPS Diluted (Quarterly) | -1.40 |
| Enterprise Value | 3.670B |
| Gross Profit Margin (Quarterly) | 84.93% |
| Profit Margin (Quarterly) | -95.71% |
| Earnings Yield | -14.07% |
| Normalized Earnings Yield | -14.12 |